Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thalidomide protocols and patient materials designed by FDA for studies without commercial sponsors.

Executive Summary

THALIDOMIDE PROTOCOLS AND PATIENT BROCHURES DESIGNED BY FDA for trials without company sponsors, FDA Deputy Commissioner Mary Pendergast told the Dermatologic & Ophthalmic Drugs Advisory Committee which convened to review the teratogenicity and neurotoxicity of thalidomide at a Nov. 7-8 meeting. Within FDA, representatives from five different divisions have "helped design [thalidomide] clinical trials and develop protocols when there is no commercial sponsor," Pendergast reported. The group has worked closely with the AIDS Clinical Trials Group on developing trials.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029196

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel